To reconfirm these results and rule out the fact that we were missing any BRAF mutations due to tumor heterogeneity issues, cancer tissue was re-punched from 2-3 different tumor areas and BRAF analysis was repeated on 400 of these 757 samples. The gene discussed is BRAF; the disease is neoplasm.